News

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

K8 was found to reduce geographic atrophy lesion area growth by more than 50% in its first human clinical trial of the drug.

In addition to the proxy statement, STAAR has reached out to all stockholders to ask for their vote to adopt the merger agreement.

The studies compared the Unity Vitreoretinal Cataract System (VCS) to the Constellation Vision System and the Centurion Vision System with Active Sentry.

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Viridian plans to submit a biologics license application (BLA) for VRDN-003 by year-end 2026.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

A new study explores the "drusen ooze" hypothesis, revealing how drusen can regress without atrophy in age-related macular degeneration.

We ask leading experts in the field what eye disease they would cure and why.

Bausch + Lomb reveals promising results for the enVista Envy IOL, showcasing superior vision outcomes in cataract surgery patients.

OpZira’s product portfolio includes AdaptDx Pro and the NOVA Vision Testing System.

Wavelight plus was first launched in China, with several European and Asia-Pacific markets following suit

Timothy Lai, MD, shares promising one-year results from the SALWEEN study on faricimab for polypoidal choroidal vasculopathy at EURETINA 2025.

From lids to retina, the 2-day event on September 26 and 27, 2025, at the Margaritaville Hollywood Beach Resort, Florida, offers a collaborative and comprehensive experience with actionable takeaways.

We ask leading experts in the field what eye disease they would cure and why.

The presence of AMD predicted an increased risk of all-cause and CVD mortality in patients with a high risk of CVD, even in the early stages of AMD.